Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug study halted early: what we learned about GSK1070806

NCT ID NCT06447506

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to check the long-term safety of an experimental drug called GSK1070806 for people with moderate to severe eczema (atopic dermatitis). It enrolled 79 adults who had already completed an earlier study of the same drug. The study was terminated early, so results are limited. The main focus was on side effects and serious health events, not on how well the drug worked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

79 people

The number who actually took part.

Started

Jun 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must sign and date the consent document. * Participants diagnosed with moderate to severe Atopic dermatitis (AtD) who have completed the qualifying Phase 2 parent study (NCT05999799) of GlaxoSmithKline (GSK's) AtD and, in their opinion, may benefit from GSK1070806. * Be intentional and able to visit the doctor at the clinic by appointment and follow all procedures related to research studies and questionnaires (able to read and understand Patient-reported outcomes (PRO) questionnaires and be able to use electronic devices). * The use of contraceptive methods for females should be consistent with local regulations on contraceptive methods of participants participating in clinical research programs. * Female participants are eligible to participate in the research program if they are not pregnant or breastfeeding and meet one of the following conditions: * It is Woman of nonchildbearing potential (WONCBP). * It is Woman of childbearing potential (WOCBP) and uses a highly effective contraceptive method that has a failure rate less than (\<) 1 percent (%) during the trial dose period and for at least 16 weeks after the last dose of the research drug. We should assess the likelihood of contraceptive failure (e.g., non-cooperation, early contraception) associated with the first dose of the drug. * WOCBP must obtain a negative result in a highly sensitive pregnancy test (by urine or serum test, as prescribed by local regulations) before receiving the first dose of the research drug. * If the urine test is positive, or the negative result cannot be confirmed (i.e., the result is unclear), a pregnancy test by serum test is required. In such cases, If the serum is tested, the test result is positive. Participants must be excluded from the research project. * Additional requirements for testing pregnancy during and after exposure to the drug. * The researcher is responsible for examining medical history, menstrual cycle history, and sexual activity in the near term. To reduce the risk of screening pregnant women who may not be detected at the beginning of pregnancy. Exclusion Criteria: * Permanent discontinuation of the study drug at any time during GSK's qualifying Phase 2 AtD (NCT05999799) or a medical condition that would hinder GSK's participation in the Phase 2 219538 (NCT05999799) AtD research project. * Participants who, during GSK's qualifying Phase 2 (NCT05999799) AtD research project, developed adverse event (AE) or Serious adverse event (SAE) based on laboratory parameters, physical examination, vital signs, Electrocardiogram (ECG), medical history, etc. Medical history, in the opinion of the researchers, suggests that if Investigational medicinal product (IMP) is continued, it may cause unnecessary risk to the participants. * Topical medications for AtD within 1 week prior to your appointment at Day 1, such as: Topical calcineurin inhibitors (TCI)/ Topical corticosteroids (TCS), Phosphodiesterase-4 (PDE-4) and Janus activation kinase inhibitors (JAKi) for external use. * Topical corticosteroids (TCS) (such as hydrocortisone, betamethasone) * Topical calcineurin inhibitors (TCI) (such as tacrolimus, pimecrolimus) * Phosphodiesterase-4 (PDE4) inhibitor for external use (e.g., crisaborole) * JAKi for external use (e.g. ruxolitinib) * Medications for topical use, or other herbal/traditional medicines that may affect the AtD that the participants are in. * Participant who received systemic therapy, which is considered contraindicated, including systemic therapy used as a rescue medication for AtD, from the screening for GSK's Phase 2 AtD 219538 research project until the LTE protocol began, were unable to participate in the research project. * Chronic uncontrolled diseases that may require immediate oral corticosteroids, such as severe uncontrolled asthma (defined as having an Asthma control questionnaire (ACQ)-5 score greater than or equal to (\>=) of 1.5 or a history of asthma exacerbations. \>= 2 times within the last 12 months, requiring systemic corticosteroid \[oral and/or intravenous medication\] or requiring a \>-24-hour hospital stay) * Experience participating in previous/current clinical research projects. * The participants have participated in any other clinical research studies. This is in addition to GSK's Phase 2 219538 (NCT05999799) research project.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • GSK Investigational Site

    Fountain Valley, California, 92708, United States

  • GSK Investigational Site

    Pompano Beach, Florida, 33334, United States

  • GSK Investigational Site

    Fayetteville, Georgia, 30214, United States

  • GSK Investigational Site

    New York, New York, 10075, United States

  • GSK Investigational Site

    Dublin, Ohio, 43016, United States

  • GSK Investigational Site

    Santa Monica, Texas, 90404, United States

  • GSK Investigational Site

    Buenos Aires, C1055AAO, Argentina

  • GSK Investigational Site

    Buenos Aires, C1181ACH, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, C1056ABI, Argentina

  • GSK Investigational Site

    Córdoba, X5000AAW, Argentina

  • GSK Investigational Site

    Rosario, S2002, Argentina

  • GSK Investigational Site

    Pleven, 5800, Bulgaria

  • GSK Investigational Site

    Sofia, 1510, Bulgaria

  • GSK Investigational Site

    Barrie, Ontario, L4M 7G1, Canada

  • GSK Investigational Site

    London, Ontario, N6H 5L5, Canada

  • GSK Investigational Site

    Markham, Ontario, L3P1X2, Canada

  • GSK Investigational Site

    Chongqing, 400016, China

  • GSK Investigational Site

    Hangzhou, 310000, China

  • GSK Investigational Site

    Shanghai, 200025, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Prague, 10034, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    La Rochelle, 17019, France

  • GSK Investigational Site

    Berlin, 10789, Germany

  • GSK Investigational Site

    Münster, 48149, Germany

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Chiba, 272-0033, Japan

  • GSK Investigational Site

    Fukuoka, 807-8556, Japan

  • GSK Investigational Site

    Fukuoka, 812-8582, Japan

  • GSK Investigational Site

    Gunma, 370-0829, Japan

  • GSK Investigational Site

    Hokkaido, 060-0033, Japan

  • GSK Investigational Site

    Hokkaido, 080-0013, Japan

  • GSK Investigational Site

    Kanagawa, 211-0063, Japan

  • GSK Investigational Site

    Osaka, 583-8588, Japan

  • GSK Investigational Site

    Osaka, 593-8324, Japan

  • GSK Investigational Site

    Saitama, 343-8555, Japan

  • GSK Investigational Site

    Chihuahua City, 31000, Mexico

  • GSK Investigational Site

    Durango, 34000, Mexico

  • GSK Investigational Site

    Guadalajara, 44628, Mexico

  • GSK Investigational Site

    Panama City, 7099, Panama

  • GSK Investigational Site

    Elblag, 82-300, Poland

  • GSK Investigational Site

    Katowice, 40-600, Poland

  • GSK Investigational Site

    Szczecin, 70-332, Poland

  • GSK Investigational Site

    Ansan, 15355, South Korea

  • GSK Investigational Site

    Seoul, 03722, South Korea

  • GSK Investigational Site

    Seoul, 04763, South Korea

  • GSK Investigational Site

    Seoul, 100 799, South Korea

  • GSK Investigational Site

    Seoul, 150-950, South Korea

  • GSK Investigational Site

    Córdoba, 14004, Spain

  • GSK Investigational Site

    Granada, 18016, Spain

  • GSK Investigational Site

    Vigo, 36206, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.